Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Diatos pre-clinical results published in linical Cancer Research


Paris, France, 1 April 2008 – Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, announced that the peer-reviewed medical journal ‘Clinical Cancer Research’ has today published positive pre-clinical in vivo efficacy and toxicology results concerning DTS-108. The research demonstrated that DTS-108 has greater anti-tumoral efficacy and safety, compared to irinotecan, as a result of an efficient and non-hepatic mode of activation. This leads to significantly higher circulating levels of the active metabolite with reduced gastrointestinal toxicity. In addition, it is anticipated that DTS-108 will bypass the inter-patient variability which is a major limitation in the therapeutic use of irinotecan. This is due to enhanced delivery of the active metabolite by using Diatos’ linker peptide technology, Vectocell®, which safe guards the efficacy whilst reducing the toxic side effects of the anti-cancer product.

Irinotecan is an effective chemotherapeutic agent that is prescribed for advanced colorectal, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The principle side effect of irinotecan is severe (grade 3-4) diarrhoea observed in 30-40% of treated patients. A significant clinical advantage should therefore be gained from the direct administration of the active metabolite, SN38, using a drug delivery technology such as Vectocell®, which delivers higher concentrations of SN38, whilst bypassing the severe side effects.

Commenting on today’s announcement, Jonathan Kearsey, Ph.D, Director of Research at Diatos, said: “The search for cytotoxic molecules with enhanced efficacy and toxicity profiles is essential for improved cancer patient care. This peer-reviewed publication represents another step in the validation of the benefits of DTS-108 versus standard of care treatment.”

“Rapid completion of the preclinical toxicology program is expected to allow Diatos to further evaluate the benefit of DTS-108 and the Vectocell® technology platform in the clinical setting.” He added.

– ends –

Notes to Editors

The publication entitled “DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies” appeared in 1st April edition of Clinical Cancer Research, Vol 14, Issue 7.

For a copy of the publication or further information on the release please contact:

Media

College Hill Life Sciences

Katja Stout / Justine Lamond / John McIntyre

Tel: +44(0)20 7866 7857

E-mail: diatos@collegehill.com
Investors

Diatos SA

Dr John Tchélingérian

President & CEO

Tel: + 33 (0)1 53 80 93 81

Email:Jtchelingerian@diatos.com

About DTS-108

DTS-108 is an oncology drug product consisting of SN38 (the active metabolite of irinotecan, CPT-11, Campto®, Camptosar®) conjugated through a chemical linker to a Vectocell® peptide. DTS-108 aims to safeguard the efficacy of SN38 while reducing the toxic effects of irinotecan.

Irinotecan is a soluble prodrug of SN38 that is the standard of care for the treatment of metastatic colorectal cancer, however, only a small proportion (2 to 8%) of irinotecan is converted into SN38, mainly by liver carboxylesterase I and/or II. The complex hepatic metabolism of irinotecan results in the accumulation of high SN38 concentrations in the intestine, which leads to severe diarrhoeas, particularly late-onset grade 3 or 4 diarrhoeas that are observed in 30 to 40% of patients. Such patients require hospitalization, dose reductions and/or treatment interruptions in some cases leading to fatalities. This complex metabolism results in significant variability in terms of both safety and efficacy, which often results in these regimens being relegated to second-line therapy. Nevertheless, the overall survival benefit of irinotecan for patients with metastatic disease can be excellent and dose intensification (when possible)


Publisher Contact Information:

Diatos SA
+ 33 (0)1 53 80 93 81
Jtchelingerian@diatos.com

Company profile of Diatos SA
Past press releases of Diatos SA.

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.